Johnson & Johnson prepares to report third-quarter results

what happened

Johnson & Johnson is due to report third-quarter results on October 12 after the closing bell, Seeking Alpha reports. Wall Street expects earnings to fall 9.6%, while revenue is projected to rise 5.8% to $25.38 billion. During the past three months, EPS estimates recorded no upward moves and 11 downward revisions. Revenue forecasts saw seven increases and three reductions, pointing to mixed analyst sentiment ahead of the release.

A Seeking Alpha analyst is positive on the quarter, citing Johnson & Johnson’s strong position in the MM therapeutics market, Tremfya and Spravato, its treatment for TRD and depressive symptoms in patients with MDD. Spravato sales are expected at $605 million, up from $584 million in Q2. Under the analyst’s base-case scenario, Tremfya sales are projected at $2.35 billion for Q3.

Investors will also assess progress toward the company’s full-year targets and any further changes to its outlook. Last quarter, J&J lifted FY26 operational sales growth guidance by $400 million, putting the range at 6.5% to 7.1% with a midpoint of $100.6 billion. The company raised its adjusted operational EPS range to $11.50–$11.65 and expects an approximately 75-basis-point improvement in adjusted pretax operating margin.

why it matters

Over the past two years, J&J has exceeded EPS estimates 88% of the time and revenue estimates 100% of the time. That track record creates a favorable setup before the report, while investors will focus on progress toward the company’s guidance.

instruments